Bio-Techne (TECH) Financials

$50.91 +3.51 (+7.41%)

Closing price 05/7/2026 04:00 PM Eastern

Extended Trading

$50.03 -0.88 (-1.73%)

As of 07:04 AM Eastern

Annual Income Statements for Bio-Techne

This table shows Bio-Techne's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	108	104	76	126	96	229	140	272	285	168	73
Consolidated Net Income / (Loss)	108	104	76	126	96	229	140	263	285	168	73
Net Income / (Loss) Continuing Operations	108	104	76	126	96	229	140	263	285	168	73
Total Pre-Tax Income	154	147	112	126	112	276	148	301	339	186	98
Total Operating Income	147	151	121	136	147	157	237	297	299	207	102
Total Gross Profit	307	337	375	432	473	483	633	756	770	770	790
Total Revenue	452	499	563	643	714	739	931	1,106	1,137	1,159	1,220
Operating Revenue	452	499	563	643	714	739	931	1,106	1,137	1,159	1,220
Total Cost of Revenue	145	162	188	211	241	255	298	349	367	389	429
Operating Cost of Revenue	145	162	188	211	241	255	298	349	367	389	429
Total Operating Expenses	160	186	254	296	327	326	396	460	471	563	688
Selling, General & Admin Expense	119	141	200	241	264	261	325	373	378	466	589
Research & Development Expense	41	45	54	55	62	65	71	87	92	97	99
Total Other Income / (Expense), net	7.14	-3.11	-8.62	-10	-35	119	-89	4.80	40	-21	-3.79
Interest Expense	1.54	1.75	7.36	10	22	19	14	11	11	16	8.51
Interest & Investment Income	0.63	0.25	0.30	0.41	0.57	0.61	0.47	0.79	3.41	3.32	3.89
Other Income / (Expense), net	8.05	-1.61	-1.57	-0.45	-14	138	-76	15	48	-8.58	0.83
Income Tax Expense	46	43	36	-0.20	16	47	8.59	38	53	18	25
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	0.00	0.00	-0.83	-8.95	0.18	0.00	0.00
Basic Earnings per Share	$2.90	$2.81	$2.04	$3.36	$2.54	$6.00	$0.91	$1.73	$1.81	$1.07	$0.47
Weighted Average Basic Shares Outstanding	37.10M	37.19M	37.31M	37.48M	37.78M	38.20M	154.99M	156.87M	157.18M	157.71M	157.52M
Diluted Earnings per Share	$2.89	$2.80	$2.03	$3.31	$2.47	$5.82	$0.87	$1.66	$1.76	$1.05	$0.46
Weighted Average Diluted Shares Outstanding	37.23M	37.33M	37.50M	38.06M	38.89M	39.40M	161.93M	164.11M	161.86M	160.77M	159.72M
Weighted Average Basic & Diluted Shares Outstanding	37.20M	37.20M	37.30M	37.50M	37.80M	38.55M	39.08M	39.21M	158.17M	158.60M	155.55M
Cash Dividends to Common per Share	$1.27	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$1.28	$0.32	$0.32	$0.32

This table shows Bio-Techne's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	51	27	49	41	34	35	23	-18	38	38	51
Consolidated Net Income / (Loss)	51	27	49	41	34	35	23	-18	38	38	51
Net Income / (Loss) Continuing Operations	51	27	49	41	34	35	23	-18	38	38	51
Total Pre-Tax Income	50	33	61	42	40	43	38	-23	48	51	71
Total Operating Income	56	38	67	46	40	47	39	-24	48	54	75
Total Gross Profit	185	177	205	203	183	194	215	199	188	191	208
Total Revenue	277	273	303	306	289	297	316	317	287	296	311
Operating Revenue	277	273	303	306	289	297	316	317	287	296	311
Total Cost of Revenue	92	96	99	103	106	103	102	118	98	105	103
Operating Cost of Revenue	92	96	99	103	106	103	102	118	98	105	103
Total Operating Expenses	129	139	138	158	143	146	176	223	140	137	133
Selling, General & Admin Expense	105	116	112	134	119	121	151	197	116	114	109
Research & Development Expense	24	23	26	24	24	25	25	26	24	23	23
Total Other Income / (Expense), net	-6.30	-4.62	-5.91	-4.16	0.18	-4.54	-0.43	1.00	0.33	-3.68	-4.27
Income Tax Expense	-1.44	5.92	12	1.07	6.57	7.99	16	-5.18	9.81	13	20
Basic Earnings per Share	$0.32	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14	($0.10)	$0.25	$0.24	$0.33
Weighted Average Basic Shares Outstanding	158.13M	157.53M	157.31M	157.71M	158.53M	158.43M	157.37M	157.52M	155.46M	155.84M	156.33M
Diluted Earnings per Share	$0.31	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14	($0.11)	$0.24	$0.24	$0.32
Weighted Average Diluted Shares Outstanding	161.94M	160.06M	160.50M	160.77M	161.12M	160.63M	158.94M	159.72M	156.36M	157.00M	157.40M
Weighted Average Basic & Diluted Shares Outstanding	158.15M	157.19M	157.58M	158.60M	158.89M	158.09M	156.77M	155.55M	155.81M	156.45M	156.57M
Cash Dividends to Common per Share	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	$0.08	-	$0.08	$0.08	$0.08

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Net Change in Cash & Equivalents	-264	9.71	27	32	-21	46	52	-27	8.00	-29	10
Net Cash From Operating Activities	139	144	144	170	182	205	352	325	254	299	288
Net Cash From Continuing Operating Activities	139	144	144	170	182	205	352	325	254	299	288
Net Income / (Loss) Continuing Operations	108	104	76	126	96	229	140	263	285	168	73
Consolidated Net Income / (Loss)	108	104	76	126	96	229	140	263	285	168	73
Depreciation Expense	37	43	60	64	78	83	88	101	107	112	110
Non-Cash Adjustments To Reconcile Net Income	4.46	15	36	50	46	-113	124	26	-18	68	143
Changes in Operating Assets and Liabilities, net	-10	-18	-28	-71	-39	6.19	1.03	-65	-120	-49	-39
Net Cash From Investing Activities	-426	-108	-306	-39	-337	27	-244	-97	-266	-203	-35
Net Cash From Continuing Investing Activities	-426	-108	-306	-39	-337	27	-244	-97	-266	-203	-35
Purchase of Property, Plant & Equipment	-20	-17	-15	-21	-25	-52	-44	-45	-38	-63	-31
Acquisitions	-420	-91	-254	-68	-289	0.00	-225	0.00	-101	-170	0.00
Purchase of Investments	0.00	0.00	-43	-8.57	-43	-68	-40	-78	-21	-5.53	0.00
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	-	0.00	0.00	2.45
Divestitures	-	-	-	-	-	-	0.00	0.00	18	0.00	0.00
Sale and/or Maturity of Investments	13	0.78	6.08	58	22	147	66	26	108	28	1.09
Other Investing Activities, net	0.05	-0.03	0.00	0.68	0.00	-	-	0.00	-232	7.00	-7.71
Net Cash From Financing Activities	31	-23	189	-99	134	-184	-63	-243	23	-122	-254
Net Cash From Continuing Financing Activities	31	-23	189	-99	134	-184	-63	-243	23	-122	-254
Repayment of Debt	-95	-59	-118	-63	-420	-189	-272	-175	-528	-256	-77
Repurchase of Common Equity	-	-	0.00	0.00	-15	-50	-43	-161	-20	-80	-276
Payment of Dividends	-47	-48	-47	-48	-48	-49	-50	-50	-50	-50	-50
Issuance of Debt	163	77	369	55	580	40	256	90	620	225	104
Other Financing Activities, net	10	6.02	-15	-43	38	64	46	53	0.92	39	45
Effect of Exchange Rate Changes	-8.18	-3.51	0.50	-	-0.31	-	6.37	-12	-3.36	-2.33	12

This table details how cash moves in and out of Bio-Techne's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-32	-19	9.78	12	36	-9.99	-37	22	-17	28	37
Net Cash From Operating Activities	59	83	81	75	64	84	41	98	28	82	87
Net Cash From Continuing Operating Activities	59	83	81	75	64	84	41	98	28	82	87
Net Income / (Loss) Continuing Operations	51	27	49	41	34	35	23	-18	38	38	51
Consolidated Net Income / (Loss)	51	27	49	41	34	35	23	-18	38	38	51
Depreciation Expense	29	28	27	28	28	27	28	27	24	25	24
Non-Cash Adjustments To Reconcile Net Income	11	20	11	26	16	18	8.64	99	1.63	18	13
Changes in Operating Assets and Liabilities, net	-31	8.13	-6.09	-20	-14	3.68	-18	-11	-37	1.44	-1.32
Net Cash From Investing Activities	-154	-24	-16	-8.81	-22	-5.03	-8.87	0.41	0.61	-5.92	-5.82
Net Cash From Continuing Investing Activities	-154	-24	-16	-8.81	-22	-5.03	-8.87	0.41	0.61	-5.92	-5.82
Purchase of Property, Plant & Equipment	-14	-15	-16	-18	-9.17	-6.82	-10	-4.89	-5.36	-5.92	-9.09
Sale and/or Maturity of Investments	26	-	-	2.18	2.49	-	1.25	-2.65	1.35	-	3.27
Net Cash From Financing Activities	72	-81	-52	-60	-12	-84	-68	-90	-44	-49	-43
Net Cash From Continuing Financing Activities	72	-81	-52	-60	-12	-84	-68	-90	-44	-49	-43
Repayment of Debt	-70	-58	-58	-70	-19	-	-8.00	-50	-46	-40	-60
Payment of Dividends	-13	-13	-13	-13	-13	-13	-13	-12	-12	-12	-13
Other Financing Activities, net	-5.83	4.20	18	23	20	4.53	15	5.99	14	3.48	30
Effect of Exchange Rate Changes	-8.69	3.42	-2.35	5.28	5.12	-5.47	-1.08	13	-1.21	0.41	-1.19
Cash Interest Paid	4.51	4.08	3.81	2.11	5.21	4.63	4.40	-	4.82	3.99	2.99
Cash Income Taxes Paid	33	4.85	7.20	-	16	21	18	-	31	5.87	5.67

This table presents Bio-Techne's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Total Assets	1,063	1,130	1,558	1,593	1,884	2,028	2,263	2,295	2,639	2,704	2,558
Total Current Assets	248	254	348	398	413	521	511	606	621	617	608
Cash & Equivalents	55	64	92	122	101	147	199	173	181	152	162
Accounts Receivable	70	93	117	120	137	123	145	195	218	241	207
Inventories, net	50	57	60	86	91	103	117	141	172	180	189
Other Current Assets	6.24	7.56	13	11	18	24	17	23	27	34	37
Other Current Nonoperating Assets	-	-	-	-	-	-	-	-	0.00	9.77	12
Plant, Property, & Equipment, net	130	132	135	145	154	177	208	223	226	251	246
Total Noncurrent Assets	685	743	1,075	1,049	1,318	1,330	1,544	1,466	1,791	1,835	1,704
Goodwill	391	431	579	598	733	728	843	822	873	973	981
Intangible Assets	293	311	452	446	579	517	616	532	535	507	366
Other Noncurrent Operating Assets	1.85	1.92	44	5.27	5.67	85	85	112	384	356	357
Total Liabilities & Shareholders' Equity	1,063	1,130	1,558	1,593	1,884	2,028	2,263	2,295	2,639	2,704	2,558
Total Liabilities	216	250	609	514	719	646	692	589	672	635	639
Total Current Liabilities	40	54	136	80	102	107	152	176	129	159	176
Accounts Payable	13	21	17	18	16	23	29	34	26	38	25
Accrued Expenses	6.60	8.37	19	20	26	9.09	15	18	15	25	26
Current Deferred Revenue	3.38	4.72	5.97	-	9.08	-	-	23	23	28	33
Current Deferred & Payable Income Tax Liabilities	1.97	1.78	2.48	8.88	5.76	2.38	5.34	13	12	3.71	11
Current Employee Benefit Liabilities	10	15	27	24	29	31	51	62	37	50	66
Other Current Liabilities	-	-	-	8.11	0.00	23	34	13	13	15	16
Total Noncurrent Liabilities	177	196	473	435	617	540	539	413	544	476	463
Long-Term Debt	73	92	344	339	493	344	329	243	350	319	346
Noncurrent Deferred & Payable Income Tax Liabilities	61	63	121	86	90	101	93	99	89	56	6.17
Other Noncurrent Operating Liabilities	42	42	8.70	9.34	34	94	117	70	105	101	111
Total Equity & Noncontrolling Interests	847	879	950	1,079	1,166	1,381	1,571	1,701	1,967	2,069	1,919
Total Preferred & Common Equity	847	879	950	1,079	1,166	1,381	1,563	1,702	1,967	2,069	1,919
Total Common Equity	847	879	950	1,079	1,166	1,381	1,563	1,702	1,967	2,069	1,919
Common Stock	164	179	200	247	317	421	535	654	723	822	913
Retained Earnings	714	771	799	877	932	1,057	1,085	1,123	1,309	1,325	1,066
Accumulated Other Comprehensive Income / (Loss)	-31	-70	-49	-45	-84	-97	-57	-75	-66	-78	-60

This table presents Bio-Techne's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	9/30/2025	12/31/2025	3/31/2026
Total Assets	2,639	2,755	2,731	2,721	2,704	2,736	2,670	2,644	2,526	2,523	2,551
Total Current Assets	621	591	591	611	617	649	635	627	610	637	688
Cash & Equivalents	181	149	130	140	152	188	178	141	145	173	210
Accounts Receivable	218	205	207	228	241	224	218	237	184	185	215
Inventories, net	172	186	181	179	180	185	188	191	203	205	201
Other Current Assets	27	52	40	31	34	43	50	54	77	74	62
Other Current Nonoperating Assets	0.00	-	27	27	9.77	9.46	1.05	4.70	0.00	0.00	0.00
Plant, Property, & Equipment, net	226	232	234	244	251	254	250	252	240	234	233
Total Noncurrent Assets	1,791	1,932	1,906	1,867	1,835	1,834	1,786	1,765	1,676	1,651	1,630
Goodwill	873	969	980	971	973	983	965	969	979	981	978
Intangible Assets	535	579	551	526	507	486	461	444	350	335	319
Other Noncurrent Operating Assets	384	384	375	369	356	365	360	353	347	335	333
Total Liabilities & Shareholders' Equity	2,639	2,755	2,731	2,721	2,704	2,736	2,670	2,644	2,526	2,523	2,551
Total Liabilities	672	758	767	707	635	597	592	626	560	512	465
Total Current Liabilities	129	128	135	150	159	142	161	169	145	140	153
Accounts Payable	26	28	32	29	38	32	33	32	30	26	23
Accrued Expenses	15	16	17	18	25	21	28	24	19	20	18
Current Deferred Revenue	23	25	28	30	28	27	28	32	30	31	38
Current Deferred & Payable Income Tax Liabilities	12	5.94	6.65	12	3.71	3.14	3.14	3.63	2.85	2.48	2.97
Current Employee Benefit Liabilities	37	35	33	44	50	42	54	62	44	45	54
Other Current Liabilities	13	17	17	16	15	18	16	16	18	15	16
Total Noncurrent Liabilities	544	630	632	557	476	455	431	457	416	371	312
Long-Term Debt	350	440	447	389	319	300	300	330	300	260	200
Noncurrent Deferred & Payable Income Tax Liabilities	89	83	72	64	56	50	38	32	11	11	14
Other Noncurrent Operating Liabilities	105	107	113	104	101	105	93	95	105	100	98
Total Equity & Noncontrolling Interests	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018	1,966	2,011	2,085
Total Preferred & Common Equity	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018	1,966	2,011	2,085
Total Common Equity	1,967	1,998	1,964	2,014	2,069	2,139	2,078	2,018	1,966	2,011	2,085
Common Stock	723	748	766	792	822	858	877	904	948	967	1,007
Retained Earnings	1,309	1,328	1,261	1,298	1,325	1,341	1,287	1,196	1,083	1,107	1,145
Accumulated Other Comprehensive Income / (Loss)	-66	-78	-64	-75	-78	-60	-86	-82	-64	-62	-67

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	6/30/2015	6/30/2016	6/30/2017	6/30/2018	6/30/2019	6/30/2020	6/30/2021	6/30/2022	6/30/2023	6/30/2024	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	26.41%	10.34%	12.82%	14.21%	11.04%	3.46%	26.04%	18.75%	2.81%	1.97%	5.23%
EBITDA Growth	8.10%	-0.29%	-6.62%	11.81%	5.56%	78.78%	-33.99%	65.58%	9.86%	-31.71%	-31.25%
EBIT Growth	-2.29%	-3.93%	-20.11%	14.04%	-1.90%	121.60%	-45.21%	92.94%	11.08%	-42.82%	-47.96%
NOPAT Growth	-6.44%	3.83%	-23.19%	66.44%	-7.74%	3.75%	71.22%	15.82%	-2.68%	-25.74%	-59.26%
Net Income Growth	-2.90%	-3.03%	-27.17%	65.80%	-23.84%	138.67%	-39.12%	88.49%	8.49%	-41.11%	-56.34%
EPS Growth	-3.67%	-3.11%	-27.50%	63.05%	-25.38%	135.63%	-39.12%	88.49%	6.02%	-40.34%	-56.19%
Operating Cash Flow Growth	1.90%	3.44%	-0.30%	18.54%	6.60%	12.99%	71.61%	-7.64%	-21.79%	17.53%	-3.82%
Free Cash Flow Firm Growth	-466.62%	114.68%	-685.47%	142.01%	-244.71%	213.51%	-93.05%	1,889.38%	-164.99%	152.14%	172.08%
Invested Capital Growth	88.71%	8.08%	36.65%	2.96%	21.99%	-2.33%	14.39%	1.77%	23.37%	5.18%	-6.06%
Revenue Q/Q Growth	5.89%	3.55%	4.03%	3.82%	1.62%	-2.10%	9.81%	2.71%	1.17%	0.41%	0.90%
EBITDA Q/Q Growth	3.54%	0.67%	5.74%	13.33%	-8.39%	10.94%	-14.61%	7.41%	15.99%	-15.34%	-24.68%
EBIT Q/Q Growth	1.56%	0.08%	4.97%	18.46%	-14.25%	13.98%	-22.29%	9.59%	21.57%	-22.43%	-40.04%
NOPAT Q/Q Growth	-0.38%	1.14%	2.63%	-1.82%	3.11%	2.90%	18.45%	-3.28%	7.12%	-16.14%	-45.12%
Net Income Q/Q Growth	-0.46%	-0.67%	2.67%	12.58%	-20.81%	22.68%	-24.05%	21.90%	4.99%	-17.19%	-44.25%
EPS Q/Q Growth	-0.69%	-0.71%	2.53%	11.45%	-21.09%	19.26%	-24.05%	21.90%	2.33%	-18.60%	-45.24%
Operating Cash Flow Q/Q Growth	-0.56%	-0.34%	10.96%	8.95%	-4.67%	-5.16%	28.09%	-5.60%	-7.06%	-2.57%	8.57%
Free Cash Flow Firm Q/Q Growth	8.80%	-95.14%	77.41%	24.74%	-56.55%	1.13%	-92.46%	1,122.05%	-13.32%	-21.44%	25.44%
Invested Capital Q/Q Growth	-0.26%	1,040.74%	-1.56%	-3.25%	1.00%	1.15%	12.92%	-1.51%	0.38%	-0.31%	-5.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	67.94%	67.46%	66.53%	67.21%	66.31%	65.41%	67.97%	68.42%	67.72%	66.41%	64.80%
EBITDA Margin	42.52%	38.42%	31.80%	31.13%	29.60%	51.15%	26.79%	37.35%	39.91%	26.73%	17.46%
Operating Margin	32.51%	30.18%	21.42%	21.18%	20.55%	21.31%	25.49%	26.83%	26.30%	17.83%	8.38%
EBIT Margin	34.29%	29.85%	21.14%	21.11%	18.65%	39.94%	17.36%	28.21%	30.48%	17.09%	8.45%
Profit (Net Income) Margin	23.82%	20.94%	13.51%	19.62%	13.46%	31.04%	14.99%	23.80%	25.11%	14.50%	6.02%
Tax Burden Percent	69.88%	70.84%	67.96%	100.16%	85.77%	82.93%	94.20%	87.30%	84.29%	90.53%	74.55%
Interest Burden Percent	99.41%	98.99%	94.07%	92.80%	84.13%	93.70%	91.66%	96.63%	97.75%	93.73%	95.52%
Effective Tax Rate	30.12%	29.16%	32.04%	-0.16%	14.23%	17.07%	5.80%	12.70%	15.71%	9.47%	25.45%
Return on Invested Capital (ROIC)	16.52%	12.61%	7.88%	11.19%	9.17%	8.76%	14.16%	15.23%	13.16%	8.62%	3.53%
ROIC Less NNEP Spread (ROIC-NNEP)	14.02%	25.40%	3.20%	6.18%	-2.74%	54.23%	-67.53%	21.79%	54.21%	-3.82%	1.81%
Return on Net Nonoperating Assets (RNNOA)	-3.40%	-0.51%	0.44%	1.24%	-0.61%	9.25%	-4.70%	0.85%	2.41%	-0.29%	0.15%
Return on Equity (ROE)	13.12%	12.10%	8.32%	12.44%	8.56%	18.01%	9.46%	16.08%	15.57%	8.33%	3.68%
Cash Return on Invested Capital (CROIC)	-44.93%	4.85%	-23.10%	8.28%	-10.64%	11.12%	0.73%	13.47%	-7.77%	3.58%	9.79%
Operating Return on Assets (OROA)	16.10%	13.59%	8.86%	8.61%	7.66%	15.09%	7.54%	13.69%	14.05%	7.42%	3.92%
Return on Assets (ROA)	11.19%	9.53%	5.66%	8.01%	5.53%	11.72%	6.51%	11.55%	11.57%	6.29%	2.79%
Return on Common Equity (ROCE)	13.12%	12.10%	8.32%	12.44%	8.56%	18.01%	9.43%	16.04%	15.57%	8.33%	3.68%
Return on Equity Simple (ROE_SIMPLE)	12.72%	11.88%	8.01%	11.69%	8.24%	16.60%	8.93%	15.46%	14.52%	8.13%	0.00%
Net Operating Profit after Tax (NOPAT)	103	107	82	136	126	131	224	259	252	187	76
NOPAT Margin	22.72%	21.38%	14.56%	21.21%	17.62%	17.67%	24.01%	23.42%	22.17%	16.14%	6.25%
Net Nonoperating Expense Percent (NNEP)	2.51%	-12.79%	4.68%	5.02%	11.91%	-45.47%	81.68%	-6.56%	-41.05%	12.44%	1.72%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	3.37%
Cost of Revenue to Revenue	32.06%	32.54%	33.47%	32.79%	33.69%	34.59%	32.03%	31.58%	32.28%	33.59%	35.20%
SG&A Expenses to Revenue	26.40%	28.23%	35.60%	37.42%	37.02%	35.28%	34.90%	33.72%	33.29%	40.24%	48.25%
R&D to Revenue	9.03%	9.06%	9.51%	8.60%	8.74%	8.83%	7.58%	7.88%	8.14%	8.34%	8.16%
Operating Expenses to Revenue	35.44%	37.29%	45.11%	46.03%	45.77%	44.10%	42.49%	41.60%	41.42%	48.58%	56.41%
Earnings before Interest and Taxes (EBIT)	155	149	119	136	133	295	162	312	346	198	103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	192	192	179	200	211	378	249	413	454	310	213
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.05	4.53	4.44	5.00	6.60	7.18	11.05	7.91	6.50	5.45	4.20
Price to Tangible Book Value (P/TBV)	20.96	28.89	0.00	154.81	0.00	72.76	166.23	38.66	22.86	19.15	14.07
Price to Revenue (P/Rev)	7.58	7.98	7.49	8.39	10.77	13.43	18.56	12.17	11.24	9.73	6.60
Price to Earnings (P/E)	31.80	38.13	55.40	42.76	80.06	43.26	123.05	49.47	44.80	67.09	109.72
Dividend Yield	1.38%	1.20%	1.13%	0.89%	0.63%	0.49%	0.29%	0.37%	0.49%	0.45%	0.62%
Earnings Yield	3.14%	2.62%	1.81%	2.34%	1.25%	2.31%	0.81%	2.02%	2.23%	1.49%	0.91%
Enterprise Value to Invested Capital (EV/IC)	4.17	4.53	3.72	4.49	5.33	6.80	10.33	7.85	6.11	5.14	3.94
Enterprise Value to Revenue (EV/Rev)	7.50	7.98	7.93	8.63	11.25	13.55	18.69	12.18	11.37	9.87	6.75
Enterprise Value to EBITDA (EV/EBITDA)	17.64	20.77	24.94	27.73	38.02	26.50	69.76	32.61	28.50	36.94	38.68
Enterprise Value to EBIT (EV/EBIT)	21.87	26.74	37.53	40.90	60.34	33.93	107.63	43.18	37.32	57.77	79.91
Enterprise Value to NOPAT (EV/NOPAT)	33.02	37.34	54.50	40.70	63.85	76.68	77.84	52.01	51.31	61.17	108.07
Enterprise Value to Operating Cash Flow (EV/OCF)	24.34	27.63	31.08	32.58	44.24	48.79	49.41	41.40	50.82	38.28	28.65
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	97.11	0.00	55.03	0.00	60.42	1,511.35	58.80	0.00	147.48	39.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.11	0.43	0.31	0.44	0.26	0.22	0.15	0.18	0.15	0.18
Long-Term Debt to Equity	0.09	0.10	0.36	0.31	0.42	0.25	0.21	0.14	0.18	0.15	0.18
Financial Leverage	-0.24	-0.02	0.14	0.20	0.22	0.17	0.07	0.04	0.04	0.08	0.08
Leverage Ratio	1.17	1.27	1.47	1.55	1.55	1.54	1.45	1.39	1.35	1.32	1.32
Compound Leverage Factor	1.17	1.26	1.38	1.44	1.30	1.44	1.33	1.35	1.31	1.24	1.26
Debt to Total Capital	8.34%	9.77%	30.10%	23.91%	30.38%	20.80%	18.02%	13.08%	15.24%	13.36%	15.28%
Short-Term Debt to Total Capital	0.44%	0.39%	4.79%	0.00%	0.95%	1.06%	0.86%	0.64%	0.15%	0.00%	0.00%
Long-Term Debt to Total Capital	7.90%	9.39%	25.31%	23.91%	29.43%	19.74%	17.16%	12.44%	15.09%	13.36%	15.28%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.43%	-0.04%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.66%	90.23%	69.90%	76.09%	69.62%	79.20%	81.55%	86.96%	84.76%	86.64%	84.72%
Debt to EBITDA	0.40	0.50	2.28	1.69	2.41	0.96	1.38	0.62	0.78	1.03	1.62
Net Debt to EBITDA	-0.18	0.00	1.40	0.79	1.62	0.24	0.46	0.02	0.33	0.54	0.86
Long-Term Debt to EBITDA	0.38	0.48	1.92	1.69	2.33	0.91	1.32	0.59	0.77	1.03	1.62
Debt to NOPAT	0.75	0.89	4.99	2.49	4.04	2.78	1.54	0.99	1.40	1.70	4.54
Net Debt to NOPAT	-0.33	-0.01	3.06	1.15	2.72	0.70	0.51	0.03	0.59	0.89	2.41
Long-Term Debt to NOPAT	0.71	0.86	4.20	2.49	3.92	2.64	1.47	0.94	1.39	1.70	4.54
Altman Z-Score	11.58	11.59	5.65	7.99	7.92	11.03	16.50	15.55	13.19	12.22	8.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.28%	0.23%	-0.02%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.24	4.69	2.57	5.01	4.05	4.88	3.35	3.44	4.84	3.87	3.46
Quick Ratio	4.55	3.49	2.03	3.80	2.98	3.69	2.48	2.51	3.29	2.47	2.10
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-279	41	-240	101	-146	166	12	229	-149	78	211
Operating Cash Flow to CapEx	700.12%	853.10%	946.84%	813.83%	714.73%	396.60%	794.93%	724.31%	665.18%	475.50%	1,006.88%
Free Cash Flow to Firm to Interest Expense	-181.00	23.46	-32.62	9.90	-6.73	8.63	0.83	20.25	-13.27	4.93	24.82
Operating Cash Flow to Interest Expense	90.26	82.47	19.52	16.72	8.37	10.69	25.24	28.76	22.68	19.00	33.79
Operating Cash Flow Less CapEx to Interest Expense	77.37	72.80	17.46	14.67	7.20	7.99	22.07	24.79	19.27	15.00	30.44
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.46	0.42	0.41	0.41	0.38	0.43	0.49	0.46	0.43	0.46
Accounts Receivable Turnover	7.23	6.11	5.36	5.42	5.54	5.68	6.95	6.50	5.50	5.04	5.44
Inventory Turnover	3.28	3.04	3.21	2.89	2.72	2.63	2.71	2.71	2.35	2.22	2.33
Fixed Asset Turnover	3.66	3.81	4.21	4.59	4.77	4.47	4.84	5.13	5.06	4.86	4.91
Accounts Payable Turnover	12.55	9.52	10.05	11.94	13.88	13.00	11.36	11.04	12.32	12.23	13.57
Days Sales Outstanding (DSO)	50.46	59.77	68.14	67.30	65.88	64.24	52.52	56.11	66.31	72.41	67.08
Days Inventory Outstanding (DIO)	111.32	119.91	113.54	126.20	134.08	138.72	134.59	134.81	155.58	164.70	156.92
Days Payable Outstanding (DPO)	29.07	38.32	36.32	30.56	26.30	28.07	32.12	33.06	29.62	29.83	26.90
Cash Conversion Cycle (CCC)	132.70	141.35	145.37	162.94	173.66	174.88	154.99	157.85	192.27	207.28	197.10
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	813	879	1,201	1,236	1,508	1,473	1,685	1,715	2,116	2,225	2,090
Invested Capital Turnover	0.73	0.59	0.54	0.53	0.52	0.50	0.59	0.65	0.59	0.53	0.57
Increase / (Decrease) in Invested Capital	382	66	322	36	272	-35	212	30	401	110	-135
Enterprise Value (EV)	3,392	3,983	4,466	5,551	8,034	10,012	17,399	13,467	12,929	11,445	8,237
Market Capitalization	3,426	3,984	4,215	5,394	7,692	9,920	17,277	13,458	12,780	11,279	8,054
Book Value per Share	$22.80	$23.63	$25.44	$28.72	$30.86	$36.14	$40.19	$43.38	$12.49	$13.13	$12.24
Tangible Book Value per Share	$4.40	$3.70	($2.18)	$0.93	($3.88)	$3.57	$2.67	$8.87	$3.55	$3.74	$3.65
Total Capital	924	975	1,358	1,418	1,674	1,744	1,917	1,957	2,320	2,388	2,265
Total Debt	77	95	409	339	509	363	345	256	354	319	346
Total Long-Term Debt	73	92	344	339	493	344	329	243	350	319	346
Net Debt	-34	-0.58	251	157	343	92	114	8.88	149	166	184
Capital Expenditures (CapEx)	20	17	15	21	25	52	44	45	38	63	29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	102	108	120	137	160	162	143	195	292	305	270
Debt-free Net Working Capital (DFNWC)	213	204	278	319	327	433	375	442	496	458	432
Net Working Capital (NWC)	209	200	213	319	311	414	358	430	493	458	432
Net Nonoperating Expense (NNE)	-4.99	2.20	5.86	10	30	-99	84	-4.19	-33	19	2.83
Net Nonoperating Obligations (NNO)	-34	-0.58	251	157	343	92	114	14	149	156	171
Total Depreciation and Amortization (D&A)	37	43	60	64	78	83	88	101	107	112	110
Debt-free, Cash-free Net Working Capital to Revenue	22.47%	21.58%	21.29%	21.32%	22.48%	21.90%	15.39%	17.64%	25.70%	26.33%	22.16%
Debt-free Net Working Capital to Revenue	47.00%	40.78%	49.31%	49.59%	45.73%	58.58%	40.26%	39.98%	43.68%	39.52%	35.46%
Net Working Capital to Revenue	46.11%	40.03%	37.74%	49.59%	43.50%	56.08%	38.49%	38.85%	43.37%	39.52%	35.46%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.73	$0.70	$0.51	$0.84	$0.64	$1.50	$0.91	$1.73	$1.81	$1.07	$0.47
Adjusted Weighted Average Basic Shares Outstanding	148.38M	148.78M	149.25M	149.90M	151.12M	152.80M	154.99M	156.88M	157.18M	157.71M	157.52M
Adjusted Diluted Earnings per Share	$0.72	$0.70	$0.51	$0.83	$0.62	$1.46	$0.87	$1.66	$1.76	$1.05	$0.46
Adjusted Weighted Average Diluted Shares Outstanding	148.92M	149.30M	150M	152.22M	155.57M	157.60M	161.93M	164.12M	161.86M	160.77M	159.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	148.67M	149.19M	149.53M	150.93M	152.25M	154.20M	156.32M	156.85M	158.17M	158.60M	155.55M
Normalized Net Operating Profit after Tax (NOPAT)	103	107	82	95	126	131	224	259	252	187	76
Normalized NOPAT Margin	22.72%	21.38%	14.56%	14.83%	17.62%	17.67%	24.01%	23.42%	22.17%	16.14%	6.25%
Pre Tax Income Margin	34.09%	29.55%	19.89%	19.59%	15.69%	37.43%	15.92%	27.26%	29.79%	16.02%	8.07%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	100.44	85.23	16.17	13.32	6.13	15.37	11.59	27.58	30.89	12.59	12.11
NOPAT to Interest Expense	66.55	61.03	11.13	13.39	5.80	6.80	16.02	22.89	22.47	11.89	8.96
EBIT Less CapEx to Interest Expense	87.54	75.56	14.11	11.27	4.96	12.68	8.41	23.61	27.48	8.59	8.76
NOPAT Less CapEx to Interest Expense	53.65	51.36	9.07	11.33	4.63	4.11	12.85	18.92	19.06	7.90	5.60
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	43.72%	45.57%	62.20%	38.03%	50.34%	21.33%	35.55%	19.07%	17.62%	29.99%	68.65%
Augmented Payout Ratio	43.72%	45.57%	62.20%	38.03%	66.38%	43.18%	66.48%	80.25%	24.47%	77.61%	444.31%

This table displays calculated financial ratios and metrics derived from Bio-Techne's official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	156,453,292.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	156,453,292.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0.33
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.70%	0.37%	3.16%	1.59%	4.52%	8.96%	4.20%	3.55%	-1.00%	-0.39%	-1.51%
EBITDA Growth	-5.86%	-35.31%	-12.01%	-39.17%	-12.54%	14.33%	-29.72%	-95.60%	5.69%	6.26%	50.37%
EBIT Growth	-12.00%	-50.82%	-16.47%	-51.52%	-18.94%	28.42%	-42.23%	-152.07%	19.18%	14.85%	95.04%
NOPAT Growth	17.97%	-38.83%	-23.38%	-44.74%	-41.81%	23.43%	-57.55%	-137.41%	13.38%	5.63%	136.85%
Net Income Growth	-43.17%	-45.08%	-30.13%	-46.23%	-34.11%	27.03%	-53.96%	-143.55%	13.65%	8.94%	125.99%
EPS Growth	-43.64%	-45.16%	-27.91%	-45.83%	-32.26%	29.41%	-54.84%	-142.31%	14.29%	9.09%	128.57%
Operating Cash Flow Growth	5.89%	29.09%	60.26%	-9.47%	7.59%	1.48%	-49.23%	30.07%	-56.82%	-2.29%	110.75%
Free Cash Flow Firm Growth	-661.01%	-442.42%	76.20%	79.73%	120.00%	122.81%	174.11%	282.26%	92.09%	60.99%	246.80%
Invested Capital Growth	25.86%	22.92%	5.90%	5.18%	-2.15%	-2.22%	-1.32%	-6.06%	-5.39%	-4.63%	-5.77%
Revenue Q/Q Growth	-8.09%	-1.57%	11.31%	0.88%	-5.44%	2.62%	6.45%	0.25%	-9.59%	3.25%	5.25%
EBITDA Q/Q Growth	-35.69%	-21.65%	43.31%	-21.66%	-7.54%	2.42%	-5.26%	-95.09%	2,113.96%	9.96%	25.89%
EBIT Q/Q Growth	-47.57%	-32.63%	76.29%	-31.61%	-12.33%	6.73%	-9.72%	-161.64%	299.75%	14.27%	38.62%
NOPAT Q/Q Growth	-28.85%	-45.61%	72.12%	-17.03%	-25.08%	15.37%	-40.80%	-173.11%	327.05%	7.49%	32.74%
Net Income Q/Q Growth	-32.45%	-46.14%	78.62%	-17.27%	-17.22%	3.84%	-35.26%	-178.26%	316.00%	-0.46%	34.30%
EPS Q/Q Growth	-35.42%	-45.16%	82.35%	-16.13%	-19.23%	4.76%	-36.36%	-178.57%	318.18%	0.00%	33.33%
Operating Cash Flow Q/Q Growth	-28.79%	39.97%	-2.56%	-6.78%	-15.37%	32.02%	-51.25%	138.82%	-71.91%	198.75%	5.16%
Free Cash Flow Firm Q/Q Growth	-29.12%	6.04%	81.83%	8.04%	227.38%	7.16%	-40.96%	126.17%	34.25%	-10.19%	27.17%
Invested Capital Q/Q Growth	8.28%	-1.79%	-0.79%	-0.31%	0.74%	-1.86%	0.13%	-5.10%	1.46%	-1.07%	-1.08%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	66.87%	64.78%	67.43%	66.43%	63.23%	65.27%	67.86%	62.72%	65.65%	64.65%	66.88%
EBITDA Margin	28.20%	22.45%	31.08%	24.14%	23.60%	23.55%	20.96%	1.03%	25.13%	26.76%	32.00%
Operating Margin	20.17%	13.94%	22.08%	14.97%	13.81%	15.96%	12.24%	-7.53%	16.63%	18.41%	24.24%
EBIT Margin	17.90%	12.25%	22.08%	14.97%	13.88%	14.43%	12.24%	-7.53%	16.63%	18.41%	24.24%
Profit (Net Income) Margin	18.41%	10.08%	16.17%	13.26%	11.61%	11.75%	7.14%	-5.58%	13.33%	12.85%	16.39%
Tax Burden Percent	102.90%	82.26%	80.31%	97.43%	83.64%	81.37%	59.02%	77.34%	79.57%	74.84%	71.67%
Interest Burden Percent	100.00%	100.00%	91.17%	90.92%	100.00%	100.00%	98.88%	95.80%	100.70%	93.25%	94.34%
Effective Tax Rate	-2.90%	17.74%	19.69%	2.57%	16.36%	18.63%	40.98%	0.00%	20.43%	25.16%	28.33%
Return on Invested Capital (ROIC)	11.55%	6.44%	9.43%	7.79%	5.97%	6.98%	3.94%	-2.98%	7.38%	7.79%	9.83%
ROIC Less NNEP Spread (ROIC-NNEP)	7.97%	3.81%	7.25%	5.13%	6.05%	5.17%	3.81%	-3.57%	7.59%	5.15%	6.33%
Return on Net Nonoperating Assets (RNNOA)	0.77%	0.29%	0.81%	0.39%	0.58%	0.52%	0.38%	-0.29%	0.48%	0.26%	0.27%
Return on Equity (ROE)	12.32%	6.73%	10.24%	8.18%	6.55%	7.50%	4.32%	-3.27%	7.86%	8.06%	10.10%
Cash Return on Invested Capital (CROIC)	-10.31%	-8.83%	4.55%	3.58%	9.37%	9.91%	7.59%	9.79%	9.24%	8.60%	11.30%
Operating Return on Assets (OROA)	8.02%	5.51%	9.58%	6.50%	5.92%	6.39%	5.52%	-3.49%	7.69%	8.62%	11.30%
Return on Assets (ROA)	8.25%	4.53%	7.01%	5.75%	4.95%	5.20%	3.22%	-2.59%	6.16%	6.01%	7.64%
Return on Common Equity (ROCE)	12.32%	6.73%	10.24%	8.18%	6.55%	7.50%	4.32%	-3.27%	7.86%	8.06%	10.10%
Return on Equity Simple (ROE_SIMPLE)	12.35%	11.42%	10.08%	0.00%	7.05%	7.61%	6.52%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	57	31	54	45	33	39	23	-17	38	41	54
NOPAT Margin	20.76%	11.47%	17.73%	14.58%	11.55%	12.99%	7.23%	-5.27%	13.23%	13.78%	17.37%
Net Nonoperating Expense Percent (NNEP)	3.58%	2.62%	2.18%	2.65%	-0.08%	1.81%	0.13%	0.60%	-0.21%	2.64%	3.50%
Return On Investment Capital (ROIC_SIMPLE)	-	1.30%	-	-	-	1.62%	0.97%	-0.74%	1.67%	1.79%	2.37%
Cost of Revenue to Revenue	33.13%	35.22%	32.57%	33.57%	36.77%	34.73%	32.14%	37.28%	34.35%	35.35%	33.12%
SG&A Expenses to Revenue	38.03%	42.43%	36.86%	43.63%	41.17%	40.89%	47.84%	62.04%	40.56%	38.43%	35.11%
R&D to Revenue	8.67%	8.41%	8.49%	7.84%	8.25%	8.42%	7.77%	8.21%	8.46%	7.82%	7.53%
Operating Expenses to Revenue	46.70%	50.84%	45.35%	51.46%	49.41%	49.31%	55.62%	70.25%	49.01%	46.24%	42.64%
Earnings before Interest and Taxes (EBIT)	50	33	67	46	40	43	39	-24	48	54	75
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	78	61	94	74	68	70	66	3.25	72	79	100
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.36	6.19	5.48	5.45	5.93	5.51	4.59	4.20	4.40	4.56	3.92
Price to Tangible Book Value (P/TBV)	23.85	28.07	21.36	19.15	18.92	17.53	15.30	14.07	13.59	13.18	10.37
Price to Revenue (P/Rev)	9.37	10.61	9.57	9.73	10.82	9.57	7.67	6.60	7.11	7.54	6.75
Price to Earnings (P/E)	43.44	54.20	54.39	67.09	84.11	72.37	70.40	109.72	110.96	112.98	74.63
Dividend Yield	0.59%	0.42%	0.46%	0.45%	0.40%	0.44%	0.55%	0.62%	0.58%	0.54%	0.61%
Earnings Yield	2.30%	1.84%	1.84%	1.49%	1.19%	1.38%	1.42%	0.91%	0.90%	0.89%	1.34%
Enterprise Value to Invested Capital (EV/IC)	4.81	5.54	5.06	5.14	5.71	5.26	4.29	3.94	4.15	4.41	3.93
Enterprise Value to Revenue (EV/Rev)	9.62	10.88	9.78	9.87	10.92	9.67	7.82	6.75	7.24	7.61	6.74
Enterprise Value to EBITDA (EV/EBITDA)	27.01	32.89	30.84	36.94	42.63	37.46	33.45	38.68	40.77	41.91	32.14
Enterprise Value to EBIT (EV/EBIT)	36.89	46.40	44.19	57.77	67.77	58.36	55.01	79.91	80.13	79.09	53.11
Enterprise Value to NOPAT (EV/NOPAT)	42.54	52.05	50.58	61.17	78.41	67.87	68.09	108.07	109.21	111.35	71.33
Enterprise Value to Operating Cash Flow (EV/OCF)	42.73	45.08	36.78	38.28	42.14	37.96	35.71	28.65	35.06	37.10	27.70
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	114.24	147.48	60.24	52.49	56.19	39.01	43.72	50.04	33.79
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.23	0.19	0.15	0.14	0.14	0.16	0.18	0.15	0.13	0.10
Long-Term Debt to Equity	0.22	0.23	0.19	0.15	0.14	0.14	0.16	0.18	0.15	0.13	0.10
Financial Leverage	0.10	0.08	0.11	0.08	0.10	0.10	0.10	0.08	0.06	0.05	0.04
Leverage Ratio	1.36	1.34	1.36	1.32	1.33	1.34	1.33	1.32	1.28	1.27	1.27
Compound Leverage Factor	1.36	1.34	1.24	1.20	1.33	1.34	1.32	1.26	1.29	1.18	1.19
Debt to Total Capital	18.11%	18.54%	16.19%	13.36%	12.30%	12.61%	14.05%	15.28%	13.24%	11.45%	8.75%
Short-Term Debt to Total Capital	0.07%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	18.04%	18.54%	16.19%	13.36%	12.30%	12.61%	14.05%	15.28%	13.24%	11.45%	8.75%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	81.89%	81.46%	83.81%	86.64%	87.70%	87.39%	85.95%	84.72%	86.76%	88.55%	91.25%
Debt to EBITDA	1.08	1.18	1.06	1.03	1.00	0.97	1.17	1.62	1.39	1.18	0.79
Net Debt to EBITDA	0.72	0.82	0.67	0.54	0.37	0.40	0.67	0.86	0.72	0.39	-0.04
Long-Term Debt to EBITDA	1.08	1.18	1.06	1.03	1.00	0.97	1.17	1.62	1.39	1.18	0.79
Debt to NOPAT	1.71	1.87	1.74	1.70	1.84	1.76	2.38	4.54	3.72	3.13	1.75
Net Debt to NOPAT	1.13	1.30	1.09	0.89	0.69	0.72	1.36	2.41	1.92	1.05	-0.09
Long-Term Debt to NOPAT	1.70	1.87	1.74	1.70	1.84	1.76	2.38	4.54	3.72	3.13	1.75
Altman Z-Score	9.84	10.81	10.75	12.03	14.12	12.99	10.23	8.79	10.63	12.15	12.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.63	4.37	4.08	3.87	4.56	3.94	3.71	3.46	4.22	4.54	4.49
Quick Ratio	2.76	2.54	2.49	2.47	2.89	2.45	2.23	2.10	2.28	2.55	2.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-413	-388	-71	-65	83	89	52	118	159	143	181
Operating Cash Flow to CapEx	436.90%	559.18%	492.59%	419.89%	696.57%	1,236.56%	406.20%	2,320.44%	3,697.72%	1,391.84%	953.79%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.45	0.45	0.43	0.43	0.43	0.44	0.45	0.46	0.46	0.47	0.47
Accounts Receivable Turnover	6.04	5.84	5.20	5.04	5.47	5.62	5.20	5.44	5.97	6.04	5.36
Inventory Turnover	2.19	2.21	2.20	2.22	2.18	2.23	2.23	2.33	2.17	2.15	2.16
Fixed Asset Turnover	5.02	5.00	4.94	4.86	4.83	4.94	4.88	4.91	4.92	5.02	4.99
Accounts Payable Turnover	12.59	13.53	13.68	12.23	13.55	12.72	13.68	13.57	13.66	14.24	15.39
Days Sales Outstanding (DSO)	60.42	62.51	70.25	72.41	66.71	64.91	70.21	67.08	61.13	60.44	68.08
Days Inventory Outstanding (DIO)	166.42	165.39	166.19	164.70	167.63	163.88	163.37	156.92	168.15	169.98	168.71
Days Payable Outstanding (DPO)	29.00	26.97	26.68	29.83	26.94	28.69	26.69	26.90	26.73	25.63	23.71
Cash Conversion Cycle (CCC)	197.84	200.94	209.76	207.28	207.40	200.10	206.89	197.10	202.55	204.79	213.08
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,291	2,250	2,232	2,225	2,242	2,200	2,203	2,090	2,121	2,098	2,075
Invested Capital Turnover	0.56	0.56	0.53	0.53	0.52	0.54	0.55	0.57	0.56	0.57	0.57
Increase / (Decrease) in Invested Capital	471	420	124	110	-49	-50	-29	-135	-121	-102	-127
Enterprise Value (EV)	11,010	12,462	11,285	11,445	12,789	11,567	9,458	8,237	8,808	9,250	8,166
Market Capitalization	10,717	12,150	11,042	11,279	12,677	11,445	9,269	8,054	8,653	9,163	8,176
Book Value per Share	$12.63	$12.42	$12.81	$13.13	$13.48	$13.08	$12.77	$12.24	$12.64	$12.91	$13.33
Tangible Book Value per Share	$2.84	$2.74	$3.29	$3.74	$4.22	$4.11	$3.83	$3.65	$4.09	$4.46	$5.04
Total Capital	2,439	2,411	2,403	2,388	2,439	2,378	2,348	2,265	2,266	2,271	2,285
Total Debt	442	447	389	319	300	300	330	346	300	260	200
Total Long-Term Debt	440	447	389	319	300	300	330	346	300	260	200
Net Debt	293	311	244	166	112	122	189	184	155	87	-9.82
Capital Expenditures (CapEx)	14	15	16	18	9.17	6.82	10	4.23	0.75	5.92	9.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	317	320	316	305	319	296	317	270	320	324	325
Debt-free Net Working Capital (DFNWC)	465	455	461	458	506	473	458	432	465	497	535
Net Working Capital (NWC)	464	455	461	458	506	473	458	432	465	497	535
Net Nonoperating Expense (NNE)	6.49	3.80	4.75	4.05	-0.15	3.70	0.26	0.98	-0.26	2.75	3.06
Net Nonoperating Obligations (NNO)	293	286	218	156	103	121	185	171	155	87	-9.82
Total Depreciation and Amortization (D&A)	29	28	27	28	28	27	28	27	24	25	24
Debt-free, Cash-free Net Working Capital to Revenue	27.69%	27.93%	27.33%	26.33%	27.22%	24.74%	26.26%	22.16%	26.30%	26.66%	26.84%
Debt-free Net Working Capital to Revenue	40.69%	39.77%	39.92%	39.52%	43.23%	39.58%	37.89%	35.46%	38.21%	40.89%	44.17%
Net Working Capital to Revenue	40.54%	39.77%	39.92%	39.52%	43.23%	39.58%	37.89%	35.46%	38.21%	40.89%	44.17%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.32	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14	($0.10)	$0.25	$0.24	$0.33
Adjusted Weighted Average Basic Shares Outstanding	158.13M	157.53M	157.31M	157.71M	158.53M	158.43M	157.37M	157.52M	155.46M	155.84M	156.33M
Adjusted Diluted Earnings per Share	$0.31	$0.17	$0.31	$0.26	$0.21	$0.22	$0.14	($0.11)	$0.24	$0.24	$0.32
Adjusted Weighted Average Diluted Shares Outstanding	161.94M	160.06M	160.50M	160.77M	161.12M	160.63M	158.94M	159.72M	156.36M	157.00M	157.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.26	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	158.15M	157.19M	157.58M	158.60M	158.89M	158.09M	156.77M	155.55M	155.81M	156.45M	156.57M
Normalized Net Operating Profit after Tax (NOPAT)	39	31	54	45	33	39	23	-17	38	41	54
Normalized NOPAT Margin	14.12%	11.47%	17.73%	14.58%	11.55%	12.99%	7.23%	-5.27%	13.23%	13.78%	17.37%
Pre Tax Income Margin	17.90%	12.25%	20.13%	13.61%	13.88%	14.43%	12.11%	-7.21%	16.75%	17.16%	22.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	20.43%	22.48%	24.82%	29.99%	33.48%	32.02%	38.45%	68.65%	64.30%	61.50%	45.47%
Augmented Payout Ratio	20.43%	58.19%	64.25%	77.61%	33.48%	79.84%	171.88%	444.31%	417.90%	308.26%	136.82%

Financials Breakdown Chart

Key Financial Trends

Bio-Techne (TECH) has shown solid operating cash flow and a stable liquidity position over the last four years, with some quarterly earnings volatility and meaningful financing activity in recent periods. Below are the main takeaways for investors from the latest four years of quarterly filings (Q2 2026 back through FY 2022), focusing on what may positively or negatively impact the stock.

Strong and recurring cash generation from operations, with Net Cash From Continuing Operating Activities around 82.4M in Q2 2026 and 98.2M in Q4 2025, indicating healthy cash flow even as net income fluctuates.
Positive free cash flow in key recent quarters (approximate CFO minus capex): about 89M in Q4 2025 and around 76M in Q2 2026, suggesting ample cash for debt service, dividends, and potential buybacks.
Stable, sizable cash balance and liquidity, with Cash & Equivalents near 173M at the latest quarter (Q2 2026), supporting operations and shareholder-friendly actions.
Consistent dividend policy, with Cash Dividends per Share of $0.08 across multiple quarters, providing a steady income stream for equity investors.
Revenue remains in a robust range (roughly 290M–320M per quarter in many periods), reflecting a durable demand base. Notably, Q3–Q4 2025 saw revenues around 316M, signaling a strong underlying business.

Capex is modest and steadied over the period, typically in the 5–15M range per quarter (Purchase of PP&E amounts), suggesting ongoing maintenance rather than heavy expansion, which supports ongoing free cash flow generation.
Earnings show some volatility by quarter, including a notable Q4 2025 net loss, indicating that quarterly profitability can swing even when cash flow remains positive. This highlights the importance of looking at cash flow alongside net income.
Share buybacks occurred in late 2025, representing cash outflows intended to support per-share metrics; this can be viewed as a neutral-to-positive leverage move depending on investor preference for buybacks vs. other uses of cash.

Q4 2025 posted a net loss (Consolidated Net Income / (Loss) of about -17.7M), underscoring quarterly earnings volatility and a reminder that cash flow strength does not guarantee every quarter profitability.
Significant financing outflows in several quarters due to debt repayments and large share repurchases, which reduced cash reserves. Examples include substantial negative net cash from financing activities in 2025 (e.g., around -68M in Q3 2025, around -60M in Q4 2025, and around -83.8M in Q2 2025).

05/08/26 07:22 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Bio-Techne's Financials

When does Bio-Techne's fiscal year end?

According to the most recent income statement we have on file, Bio-Techne's financial year ends in June. Their financial year 2025 ended on June 30, 2025.

How has Bio-Techne's net income changed over the last 10 years?

Bio-Techne's net income appears to be on an upward trend, with a most recent value of $73.40 million in 2025, falling from $107.74 million in 2015. The previous period was $168.11 million in 2024. View Bio-Techne's forecast to see where analysts expect Bio-Techne to go next.

What is Bio-Techne's operating income?

Bio-Techne's total operating income in 2025 was $102.26 million, based on the following breakdown:

Total Gross Profit: $790.27 million
Total Operating Expenses: $688.02 million

How has Bio-Techne's revenue changed over the last 10 years?

Over the last 10 years, Bio-Techne's total revenue changed from $452.25 million in 2015 to $1.22 billion in 2025, a change of 169.7%.

How much debt does Bio-Techne have?

Bio-Techne's total liabilities were at $639.06 million at the end of 2025, a 0.6% increase from 2024, and a 195.3% increase since 2015.

How much cash does Bio-Techne have?

In the past 10 years, Bio-Techne's cash and equivalents has ranged from $54.53 million in 2015 to $199.09 million in 2021, and is currently $162.19 million as of their latest financial filing in 2025.

How has Bio-Techne's book value per share changed over the last 10 years?

Over the last 10 years, Bio-Techne's book value per share changed from 22.80 in 2015 to 12.24 in 2025, a change of -46.3%.

Related Companies

Financial statements for NASDAQ:TECH last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Techne (TECH) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Bio-Techne's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Techne (TECH) Financials

Annual Income Statements for Bio-Techne

Quarterly Income Statements for Bio-Techne

Annual Cash Flow Statements for Bio-Techne

Quarterly Cash Flow Statements for Bio-Techne

Annual Balance Sheets for Bio-Techne

Quarterly Balance Sheets for Bio-Techne

Annual Metrics And Ratios for Bio-Techne

Quarterly Metrics And Ratios for Bio-Techne

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Bio-Techne's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools